Universitätsklinikum Schleswig-Holstein

Running trials

• Recruiting

  FUNCtion ALS: Aiming to Restore UNC13A Function in People Living With ALS

  NCT07674667· Phase 1/2· Source

• Recruiting

  A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis

  NCT07571174· Phase 1· Source

• Active, not recruiting

  Phase IIB Study of PHENOGENE-1A (Cromolyn) as an Adjuvant Therapy in Mild to Moderate ALS

  2025-520688-42-00· Phase 2· Source

• Recruiting

  A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

  NCT07218380· Phase 3· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06793215· Phase 3· Source

• Recruiting

  Long-term Evaluation of the SIMEOX Device at Home in Non-cystic Fibrosis Bronchiectasis

  NCT06487273· Source

• Recruiting

  The Fourth Left Atrial Appendage Occlusion Study

  NCT05963698· Source

• Recruiting

  Prevention Of Sudden Cardiac Death After Myocardial Infarction by Defibrillator Implantation

  NCT05665608· Source

• Recruiting

  Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2

  NCT04628026· Phase 3· Source

• Active, not recruiting

  HANSE - Holistic Implementation Study Assessing a Northern German Interdisciplinary Lung Cancer Screening Effort

  NCT04913155· Source

• Active, not recruiting

  First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.

  NCT04767594· Source

• Active, not recruiting

  Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics

  NCT03897127· Phase 3· Source

• Active, not recruiting

  REDUCE LAP-HF III Corvia Protocol 1701

  NCT03191656· Source

• Recruiting

  International HIT-MED Registry (I-HIT-MED)

  NCT02417324· Source

• Recruiting

  Praegnant Breast Cancer: Early/Advanced/Metastatic

  NCT02338167· Source

• Active, not recruiting

  Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

  NCT01874353· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• ALS (motor neurone disease)2 recruiting
• Acute myeloid leukaemia1 recruiting
• Atrial fibrillation1 recruiting
• Bladder cancer1 recruiting
• Childhood cancers1 recruiting
• Coronary artery disease1 recruiting
• Cystic fibrosis1 recruiting
• Lung cancer1 recruiting
• Metastatic breast cancer1 recruiting
• Myelodysplastic syndromes1 recruiting
• Stroke1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment

  NCT05999968· Phase 1· Source

• Completed

  Computed Tomography-Guided Catheter Ablation for Ventricular Tachycardia

  NCT05225935· Source

• Completed

  Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment

  NCT04511455· Phase 2· Source

• Completed

  A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

  NCT04256421· Phase 3· Source

• Completed

  BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients

  NCT03944356· Source

• Completed

  Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

  NCT03353831· Phase 3· Source

• Completed

  TRAMmoniTTR Study Genetic Screening of an At-risk Population for hATTR and Monitoring of TTR Positive Subjects

  NCT03237494· Source

• Completed

  A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

  NCT02975934· Phase 3· Source

• Terminated

  Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy

  NCT03013946· Phase 3· Source

• Completed

  Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

  NCT02902029· Phase 2· Source

• Terminated

  Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

  NCT02051218· Phase 3· Source